A German team of researchers has identified a particularly powerful antibody capable of neutralizing a wide diversity of HIV-1 strains, opening new perspectives for the prevention and treatment of the infection.
In this study, scientists performed an in-depth analysis at the single cellular level of 32 elite controllers exhibiting exceptional neutralizing activity. Out of 831 monoclonal antibodies produced in the laboratory from their B lymphocytes, one candidate stood out for its exceptional performance: the 04_A06 antibody.
Remember that some people infected with HIV Human immunodeficiency virus. In English: HIV (Human Immunodeficiency Virus). Isolated in 1983 at the Pasteur Institute in Paris; recent discovery (2008) rewarded by the Nobel Prize in Medicine awarded to Luc Montagnier and Françoise Barré-Sinoussi. manage to control the infection naturally without antiretroviral treatment. These exceptional individuals, called “elite controllers,” represent less than 1% of people living with HIV. Their immune system produces particularly effective antibodies against the virus, making them a valuable source for therapeutic research.
An antibody with remarkable performance
04_A06 belongs to the category of broad neutralizing antibodies (bnAbs), capable of blocking many variants of HIV-1. Its characteristics are impressive: it neutralizes 98.5% of the 332 viral strains tested, coming from different subtypes of the virus around the world (multiclades). Its potency is also remarkable, with a median inhibitory concentration of only 0.059 micrograms per milliliter.
This antibody targets the CD4 binding site (CD4bs), a region of the viral envelope that allows HIV-1 to attach to T lymphocytes. This region is particularly interesting because it is highly conserved across viral strains, which explains the broad-spectrum effectiveness of the antibody.
Structural analysis of the antibody revealed molecular mechanisms that contribute to its exceptional breadth and potency. The most notable feature of 04_A06 is an ultra-long insertion of 11 amino acids in the heavy chain framework region 1 (FWRH1), which makes contacts with highly conserved residues on the adjacent gp120 protomer: K207, H66, and H72. These residues are functionally critical for the virus. Pseudoviruses carrying substitutions at these positions exhibit reduced or completely abolished infectivity, suggesting that escape mutations at these sites would incur costs of fitness important for the virus. To date, among all antibodies identified, only 04_A06 contacts this conserved surface of the HIV-1 envelope, a region that is sterically difficult for antibodies to access.
To evaluate the robustness of this antibody, the researchers tested it against 35 viral strains resistant to VRC01. The results are eloquent: while antibodies 1-18 and N6 neutralized 57% and 60% of these resistant variants respectively, 04_A06 neutralized 77% with greater power. In vivo experiments on humanized mice infected with HIV-1YU2 confirmed this performance. 04_A06 maintained complete and sustained viral suppression, extending up to 28 days after treatment interruption.
Promising applications for prevention
Beyond treatment, this antibody could play a major role in preventing HIV-1 infection. 04_A06 demonstrated high activity against currently circulating viruses in these prevention trials: it neutralized 98.4% of the 191 isolates tested with a median inhibitory concentration of 0.082 micrograms per milliliter.
An optimized version of the antibody, called 04_A06LS (the LS modification by amino acid substitution extends its half-life in the body), was the subject of modeling in silico. These simulations predict that a single administration of 04_A06LS at a standard dose could provide preventive efficacy similar to that of triple combinations of other bnAbs currently in early clinical investigation, with preventive efficacy greater than 93%.
This research also illustrates the importance of studying exceptional natural immune responses: elite controllers continue to share their immunological secrets with us and may well hold the keys to lasting solutions against HIV-1 infection. Clinical trials will be necessary to confirm these promising results obtained in vitro and in vivo in animals, but 04_A06 is already emerging as a leading candidate with promising potential for clinical development.
Bibliography
Gieselmann L, DeLaitsch AT, Rohde M, Gruell H, Kreer C, Ercanoglu MS, et al. Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy. Nat Immunol. 2025;26:2016-29. doi: 10.1038/s41590-025-02286-5
